Medicated coatings for implantable medical devices including polyacrylates

• US 8,110,211 B2
• Filed: 09/22/2004
• Issued: 02/07/2012
• Est. Priority Date: 09/22/2004
• Status: Active Grant

• Current Assignee: Advanced Cardiovascular Systems Incorporated
• Original Assignee: Advanced Cardiovascular Systems Incorporated
• Inventors: Pacetti, Stephen Dirk, Glauser, Thierry
• Primary Examiner(s): Wax, Robert A
• Assistant Examiner(s): HELM, CARALYNNE E
• Application Number:
  US10/948,036
• Publication Number:
  US 20060062824A1
• Time in Patent Office: 2,694 Days
• Field of Search: None
• US Class Current: 424/423
• CPC Class Codes: A61L 2300/00 Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: C08L 33/10 Homopolymers or copolymers of methacrylic acid esters

Abstract

A polymer for a medical device, particularly for a drug eluting stent, is described. The polymer can be derived from n-butyl methacrylate and can have a degree of an elongation at failure from about 20% to about 500%.

Claims

1. A medical article comprising an implantable medical device comprising a base-polymer-unit-derived polymer with a degree of an elongation at failure from about 20% to about 500% wherein the base-polymer-unit-derived polymer is poly(n-butyl methacrylate-co-lauryl methacrylate).

2. The medical article of claim 1 wherein the implantable medical device is a stent.

3. The medical article of claim 1 wherein the base polymer has a weight average molecular weight of about 200,000 Daltons to about 1,000,000 Daltons.

4. The medical article of claim 1 wherein the base polymer has a polydispersity index of about 3 to about 6.

5. The medical article of claim 1 wherein the base-polymer-unit-derived polymer has a glass transition temperature below about 20°

C.

6. The medical article of claim 5 wherein the glass transition temperature is about −

30°

C. to about 20°

C.

7. The medical article of claim 1 wherein the medical device further comprises one or any combination of vascular-smooth-muscle-cell-activity inhibitors, antiproliferatives, antineoplastics, antimitotics, anti-inflammatories, antiplatelets, anticoagulants, antifibrins, antithrombins, antibiotics, antiallergics and antioxidants.

8. The medical article of claim 5 wherein the medical device further comprises one or any combination of vascular-smooth-muscle-cell-activity inhibitors, antiproliferatives, antineoplastics, antimitotics, anti-inflammatories, antiplatelets, anticoagulants, antifibrins, antithrombins, antibiotics, antiallergics and antioxidants.

9. A method comprising depositing a coating on an implantable medical device wherein the coating comprises a base-polymer-unit-derived polymer with a degree of an elongation at failure of about 20% to about 500%, wherein the base-polymer-unit-derived polymer is poly(n-butyl methacrylate-co-lauryl methacrylate).

10. The method of claim 9 wherein the implantable medical device is a stent.

11. The method of claim 9 wherein the base polymer has a weight average molecular weight of about 200,000 Daltons to about 1,000,000 Daltons.

12. The method of claim 11 wherein the base polymer has a polydispersity index of about 3 to about 6.

13. The method of claim 9 wherein the base polymer has a polydispersity index of about 3 to about 6.

14. The method of claim 9 wherein the copolymer has a glass transition temperature below about 20°

C.

15. The method of claim 14 wherein the glass transition temperature of about −

30°

C. to about 20°

C.

16. The method of claim 9 wherein the medical device further comprises one or any combination of vascular-smooth-muscle-cell-activity inhibitors, antiproliferatives, antineoplastics, antimitotics, anti-inflammatories, antiplatelets, anticoagulants, antifibrins, antithrombins, antibiotics, antiallergics and antioxidants.

17. The method of claim 15 wherein the medical device further comprises one or any combination of vascular-smooth-muscle-cell-activity inhibitors, antiproliferatives, antineoplastics, antimitotics, anti-inflammatories, antiplatelets, anticoagulants, antifibrins, antithrombins, antibiotics, antiallergics and antioxidants.